Cystic fibrosis alters the structure of mucus in airways

June 27, 2017

Mucus is important for maintaining healthy lungs. Inhaled particles, including bacteria and viruses, get trapped in mucus and then cilia -- tiny hair like projections on the surface of the airway cells -- sweep the mucus out of the airway.

In lungs affected by cystic fibrosis (CF), the mucus is abnormal and the lung-clearing process breaks down. This deficit may contribute to lung infections and inflammation that cause serious, life-shortening illness in people with CF.

In a new study, published in Proceedings of the National Academy of Sciences (PNAS) Early Edition, University of Iowa researchers led by Michael Welsh, MD, director of the UI Pappajohn Biomedical Institute, professor of internal medicine in the UI Carver College of Medicine, and a Howard Hughes Medical Institute investigator, and Lynda Ostedgaard, PhD, investigated how CF alters the structure of mucus produced in airway passages. The study focused on two gel-forming mucin proteins, MUC5B and MUC5AC, that are the major components of airway mucus. Studying these two proteins in pigs, the researchers found that they have distinct and different structures and origins. MUC5B is produced by submucosal glands in the form of strands, while MUC5AC is secreted by goblet cells as wispy threads and thin sheets. The study also showed that once these two types of mucus protein emerge onto the airway surface, they combine so that the MUC5B strands are partly covered with MUC5AC sheets. This overall structure may be helpful for capturing and clearing inhaled particles.

However, in pig airways that are affected by CF, these mucins look different. The strands of MUC5B become tangled, and often fill the submucosal gland ducts and fail to detach properly, and MUC5AC sheets are larger and more abundant.

"We generally think of mucus that covers the airways as a homogeneous material," says Ostedgaard, UI research associate professor of internal medicine, and first author of the study. "This work reveals that mucus from submucosal glands and mucus from goblet cells have different morphological structures. These structures may serve different purposes in clearing particulates and bacteria from our lungs. Our study also shows how these structures are abnormal in cystic fibrosis, explaining why patients with this disease have difficulty clearing mucus from their lungs."

The next step will be to understand why airways produce these different types of mucus structures and learn whether the different mucus structures actually play a role in CF lung disease, and other airway diseases like asthma and COPD

"Our observations make us think differently about how mucus functions in the airway, and how that might change in lung diseases like cystic fibrosis," Ostedgaard says. A better understanding of the structure and proper function of airway mucus might help us understand how abnormal mucus develops in CF, and even point us to new ways to treat or prevent lung disease."
-end-
In addition to Ostedgaard and Welsh, the UI team also included Tom Moninger, James McMenimen, Nicholas Swain, Connor Parker, Ian Thornell, Linda Powers, Nicholas Gansemer, Drake Bouzek, Daniel Cook, David Meyerholz, Mahmoud Abou Alaiwa, and David Stoltz.

The research was supported in part by grants from the National Heart, Lung and Blood Institute, the Cystic Fibrosis Foundation and the Roy J. Carver Charitable Trust.

University of Iowa Health Care

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.